Trial Search Results
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: This phase 2 trial is studying how well giving combination chemotherapy together with low-dose radiation therapy works in treating patients with stage I or stage IIA Hodgkin's lymphoma.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Stanford University
Stanford Investigator(s):
Intervention(s):
- Drug: Vincristine
- Drug: Cyclophosphamide
- Drug: Doxorubicin
- Drug: Prednisone
- Drug: Bleomycin
- Drug: Etoposide
- Radiation: Low-dose radiotherapy (RT)
Phase:
Phase 2
Eligibility
INCLUSION CRITERIA:
- Diagnosis of previously untreated stage I or IIA Hodgkin's lymphoma, eligible subtypes
- Nodular sclerosis
- Mixed cellularity
- Classical, not otherwise specified
- Age ≥ 18 years and ≤ 70 years
- Granulocytes ≥ 2 x 10e6/µL
- Platelets ≥ 150 x 10e6/µL
- Bilirubin ≤ 2.5 mg/dL
- Serum creatinine ≤ 2 mg/dL
- Patients > 50 years or those with a history of cardiac disease should have an ejection
fraction ≥ 50%
- All scans, X-rays, laboratory tests must be performed within 6 weeks of enrollment
- Pathologic material reviewed at Stanford University
- Evaluation by Stanford Medical Oncology and Radiation Oncology with review at the
Hodgkin's Disease Staging Conference
- Written informed consent
EXCLUSION CRITERIA:
- Lymphocytic predominance Hodgkin's disease
- Prior treatment for Hodgkin's disease
- Mediastinal mass equal to or greater than one-third the maximum intrathoracic diameter
on a standing posteroanterior chest x-ray
- Any lymph node mass > 10 cm in greatest trans-axial diameter
- Two or more extranodal sites of disease
- Constitutional (B) symptoms present at diagnosis
- Prior or concurrent malignancies within 5 years (EXCEPTION: basal cell carcinoma of
the skin)
- Any medical contraindication to the planned treatment, including:
- Pregnant
- Positive antibody test for the human immunodeficiency virus (HIV)
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Anne Wiley
6507256432